Vor Bio Completes Enrollment for Phase 3 MG Trial

The company reports a $86.7 million quarterly loss as it pushes for 2027 clinical trial results for its autoimmune drug.

Updated on Oct. 30, 2026 in Biotech

Vor Bio Completes Enrollment for Phase 3 MG Trial

Live Poll

Do you trust biotechnology companies' public projections for their future financial stability and clinical success?

Vor Bio reported a net loss of $86.7 million for the third quarter ending September 30, 2026, while completing enrollment for its Phase 3 UPSTREAM MG clinical trial. The company maintains an operational runway projected to last into early 2029.

Why it matters

The company is scaling development efforts for telitacicept to address generalized myasthenia gravis, a chronic autoimmune disorder, following successful clinical signals in international studies.

Telitacicept functions through dual inhibition of BLyS and APRIL cytokines, targeting autoreactive B cells. In a prior China-based trial, 42.1% of treated participants achieved minimal symptom expression over 48 weeks.

The players

Vor Bio

A Boston-based biotechnology company focused on developing therapies for hematological and autoimmune diseases.

The details

The drug works by simultaneously blocking BLyS (B-lymphocyte stimulator) and APRIL (a proliferation-inducing ligand), two cytokines that drive the survival of B cells—the white blood cells responsible for producing disease-causing autoantibodies. By inhibiting these signaling molecules, the therapy reduces the production of pathogenic antibodies in patients with autoimmune conditions. Researchers are now testing this mechanism in the UPSTREAM MG study to see if the therapeutic effect holds across different patient populations.

September 30, 2026: End of the third fiscal quarter.
October 30, 2026: Publication date of the quarterly financial results.
First half of 2027: Expected topline results for the UPSTREAM MG trial and first patient dosing for the oMG trial.
Early 2029: Projected end of the company's operational cash runway.

The Tech Race

Vor Bio is working to bridge clinical data established in China to validate telitacicept in new markets. This effort follows the drug's success across multiple autoimmune indications, including Sjögren's disease and IgA nephropathy.

The study enrollment completion is a prerequisite for potential FDA review of telitacicept. Patients with generalized myasthenia gravis will not have access to the therapy until the completion of these Phase 3 clinical milestones.

The takeaway

The company's focus remains on shifting from early-phase observations to definitive Phase 3 data for its lead autoimmune candidate. Stakeholders should monitor the projected topline results for the UPSTREAM MG trial expected in the first half of 2027.

What happens next

Topline results for the Phase 3 UPSTREAM MG trial are anticipated in the first half of 2027, followed by the expected commencement of patient dosing for the UPSTREAM oMG trial in the same period.